IL143299A0 - Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation - Google Patents

Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation

Info

Publication number
IL143299A0
IL143299A0 IL14329999A IL14329999A IL143299A0 IL 143299 A0 IL143299 A0 IL 143299A0 IL 14329999 A IL14329999 A IL 14329999A IL 14329999 A IL14329999 A IL 14329999A IL 143299 A0 IL143299 A0 IL 143299A0
Authority
IL
Israel
Prior art keywords
methyl
thiadiazolidine
quinazolinyl
dione
dihydro
Prior art date
Application number
IL14329999A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Reddy Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Reddy Research Foundation filed Critical Novo Nordisk As
Publication of IL143299A0 publication Critical patent/IL143299A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14329999A 1998-12-01 1999-11-29 Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation IL143299A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801580 1998-12-01
PCT/DK1999/000663 WO2000032191A1 (fr) 1998-12-01 1999-11-29 Nouvelle composition pharmaceutique et procede de preparation

Publications (1)

Publication Number Publication Date
IL143299A0 true IL143299A0 (en) 2002-04-21

Family

ID=8106261

Family Applications (3)

Application Number Title Priority Date Filing Date
IL14329999A IL143299A0 (en) 1998-12-01 1999-11-29 Pharmaceutical composition comprising 5-[[4- [3-methyl-4-oxo-3, 4-dihydro-2-quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine-2, 4-dione and the process for its preparation
IL143299A IL143299A (en) 1998-12-01 2001-05-22 Pharmaceutical preparation containing 5 - [[- [3-methyl - 4 - oxo - 3,4 - dehydro - quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine - 2,4 - deion and process for its preparation
IL179865A IL179865A (en) 1998-12-01 2006-12-05 Pharmaceutical composition comprising 5 - [[4-[3 - methyl- 4- oxo - 3,4 - dihydro - 2 - quinazolinyl]methoxy] phenyl-methyl]thiadiazolidine-2,4- dione in the form of a tablet, a powder or a capsule and process for its preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL143299A IL143299A (en) 1998-12-01 2001-05-22 Pharmaceutical preparation containing 5 - [[- [3-methyl - 4 - oxo - 3,4 - dehydro - quinazolinyl] methoxy] phenyl-methyl] thiadiazolidine - 2,4 - deion and process for its preparation
IL179865A IL179865A (en) 1998-12-01 2006-12-05 Pharmaceutical composition comprising 5 - [[4-[3 - methyl- 4- oxo - 3,4 - dihydro - 2 - quinazolinyl]methoxy] phenyl-methyl]thiadiazolidine-2,4- dione in the form of a tablet, a powder or a capsule and process for its preparation

Country Status (21)

Country Link
US (1) US7439248B1 (fr)
EP (1) EP1135127B1 (fr)
JP (2) JP5524435B2 (fr)
KR (1) KR100690311B1 (fr)
CN (1) CN1158075C (fr)
AT (1) ATE316376T1 (fr)
AU (1) AU776299B2 (fr)
BR (1) BR9915835A (fr)
CA (1) CA2352430C (fr)
CZ (1) CZ300543B6 (fr)
DE (1) DE69929635T2 (fr)
ES (1) ES2257886T3 (fr)
HU (1) HUP0104544A3 (fr)
IL (3) IL143299A0 (fr)
NO (1) NO329909B1 (fr)
PL (1) PL197077B1 (fr)
RU (1) RU2233659C2 (fr)
TW (1) TWI235657B (fr)
UA (1) UA75569C2 (fr)
WO (1) WO2000032191A1 (fr)
ZA (1) ZA200104261B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL197077B1 (pl) * 1998-12-01 2008-02-29 Reddys Lab Inc Dr Kompozycja farmaceutyczna zawierająca 5-[[4-[3-metylo-4-okso-3,4-dihydro-2-chinazolinylo]metoksy]fenylometylo]-tiazolidyno-2,4-dion lub jego sól dopuszczalną do stosowania w farmacji i sposób jej wytwarzania
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
JP2004506609A (ja) 2000-05-26 2004-03-04 ノボ　ノルディスク　アクティーゼルスカブ 新たなる医薬組成物及びその調製の為の方法
AU2000249111A1 (en) * 2000-05-30 2001-12-11 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
CA2469940A1 (fr) * 2001-12-19 2003-06-26 Takeda Chemical Industries, Ltd. Compositions solides comprenant des composes instables a l'oxygene et procede de stabilisation de ces composes
WO2006002255A2 (fr) * 2004-06-23 2006-01-05 Dr. Reddy's Laboratories Ltd. Preparation pharmaceutique de balaglitazone
CL2008000596A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280997A (en) * 1978-12-08 1981-07-28 Johannes Van Leverink Extrusion process for the preparation of anhydrous stable lactose
DE3433239A1 (de) * 1984-09-11 1986-03-20 Bayer Ag, 5090 Leverkusen Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung
CA2019324C (fr) * 1989-07-10 1996-08-20 Robert L. Jerzewski Comprimes de fosinopril
IT1238072B (it) * 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
SK121193A3 (en) * 1991-04-04 1994-07-06 Procter & Gamble Chewable antacid compositions
SK117793A3 (en) * 1991-04-29 1994-05-11 Merck & Co Inc Optimized tablet formulation
TW268952B (fr) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
AU7719894A (en) * 1993-09-03 1995-03-22 Smithkline Beecham Corporation Stabilized tablet formulation
US5532256A (en) 1994-05-18 1996-07-02 American Home Products Corporation New azolidinediones and thiadiazolidinediones as antihyperglycemic agents
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
WO1996018386A1 (fr) * 1994-12-14 1996-06-20 Enbalt Trading Limited Formulations de comprimes pharmaceutiques elabores par compression directe
US6395303B1 (en) * 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
JPH09249561A (ja) * 1996-03-15 1997-09-22 Teikoku Chem Ind Corp Ltd 医薬組成物
HU222109B1 (hu) * 1996-09-10 2003-04-28 EGIS Gyógyszergyár Rt. Captopriltartalmú tabletták és eljárás ezek előállítására
DK0958296T3 (da) * 1996-12-31 2003-08-18 Reddys Lab Ltd Dr Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
JP2002510283A (ja) 1997-12-02 2002-04-02 ドクター・レディーズ・リサーチ・ファウンデーション 抗糖尿病性、低脂質性及び抗高血圧性を有する置換チアゾリンジオンとオキサゾリジンジオン
EP0945134A1 (fr) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Nouvelles formes galeniques du meloxicam pour administration par voie orale
PL197077B1 (pl) * 1998-12-01 2008-02-29 Reddys Lab Inc Dr Kompozycja farmaceutyczna zawierająca 5-[[4-[3-metylo-4-okso-3,4-dihydro-2-chinazolinylo]metoksy]fenylometylo]-tiazolidyno-2,4-dion lub jego sól dopuszczalną do stosowania w farmacji i sposób jej wytwarzania
JP2004506609A (ja) * 2000-05-26 2004-03-04 ノボ　ノルディスク　アクティーゼルスカブ 新たなる医薬組成物及びその調製の為の方法
WO2006002255A2 (fr) 2004-06-23 2006-01-05 Dr. Reddy's Laboratories Ltd. Preparation pharmaceutique de balaglitazone

Also Published As

Publication number Publication date
HUP0104544A3 (en) 2003-12-29
IL179865A0 (en) 2007-05-15
KR100690311B1 (ko) 2007-03-09
CA2352430C (fr) 2008-11-18
AU1376200A (en) 2000-06-19
EP1135127A1 (fr) 2001-09-26
EP1135127B1 (fr) 2006-01-25
CN1356901A (zh) 2002-07-03
NO20012673L (no) 2001-05-31
CN1158075C (zh) 2004-07-21
CZ300543B6 (cs) 2009-06-10
ZA200104261B (en) 2002-05-24
PL348601A1 (en) 2002-06-03
CA2352430A1 (fr) 2000-06-08
BR9915835A (pt) 2001-08-21
ATE316376T1 (de) 2006-02-15
WO2000032191A1 (fr) 2000-06-08
IL179865A (en) 2009-12-24
CZ20011832A3 (cs) 2001-10-17
HUP0104544A2 (en) 2002-08-28
UA75569C2 (en) 2006-05-15
TWI235657B (en) 2005-07-11
DE69929635D1 (de) 2006-04-13
RU2233659C2 (ru) 2004-08-10
JP5524435B2 (ja) 2014-06-18
DE69929635T2 (de) 2006-09-21
IL143299A (en) 2006-12-31
NO329909B1 (no) 2011-01-24
KR20010099827A (ko) 2001-11-09
US7439248B1 (en) 2008-10-21
JP2012144560A (ja) 2012-08-02
ES2257886T3 (es) 2006-08-01
PL197077B1 (pl) 2008-02-29
NO20012673D0 (no) 2001-05-31
AU776299B2 (en) 2004-09-02
JP2002531404A (ja) 2002-09-24

Similar Documents

Publication Publication Date Title
HUP0203841A3 (en) 5-membered heteroaromatic compounds and use thereof for preparation of pharmaceutical compositions, and pharmaceutical compositions containing them
WO2000017190A3 (fr) Derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
AU2001236457A1 (en) Compounds and compositions for delivering active agents
HUP0303069A3 (en) Imidazole derivatives, pharmaceutical compositions containing them and their use
HUP0200355A2 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0203403A3 (en) New imidazole derivatives, pharmaceutical compositions containing them and their use
WO2000057900A3 (fr) Facteur
HUP0204413A3 (en) Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them
ZA200206905B (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same.
AU2001237525A1 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
HUP0203902A3 (en) Substituted oxazolidinones, process for their preparation and pharmaceutical compositions containing them and their use
IL158168A0 (en) 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same
HUP0103283A3 (en) Pyrazinone protease inhibitors, pharmaceutical compositions containing them and use of the compounds
AU2001284985A1 (en) Compounds and compositions for delivering active agents
HUP0400832A3 (en) New amidoalkyl-piperidine and amidoalkyl-piperazine derivatives, and pharmaceutical compositions containing such derivatives as active ingredients
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
AU2001228811A1 (en) Nitrogen-containing 5-membered cyclic compounds and drugs containing these compounds as the active ingredient
AU2001288277A1 (en) Compounds and compositions for delivering active agents
IL179865A0 (en) Pharmaceutical composition comprising 5 - [[4-[3 - methyl- 4- oxo - 3,4 - dihydro - 2 - quinazolinyl]methoxy] phenyl-methyl]thiadiazolidine-2,4- dione in the form of a tablet a powder or a capsule and the process for its preparation
AU2001268131A1 (en) Stabilized compositions containing oxygen-labile active agents
HUP0202520A3 (en) Substituted benzylthiazolidine-2,4-dione derivatives and pharmaceutical compositions containing them
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HUP0303636A3 (en) Dihydronaphthalenederivative compounds and pharmaceutical compositions containing them as active ingredient

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed